Want to see ELMD full AI Analyst Report?
Earnings Data
Report Date
Sep 01, 2026After Close (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
0.32Last Year’s EPS
0.25Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights strong, broad-based financial performance (double-digit revenue growth, high operating leverage, margin durability), improved operational capability (completed manufacturing optimization, ePrescribe adoption), a healthy balance sheet (cash, no debt) and a large addressable bronchiectasis market supported by active clinical and digital outreach. Challenges include modest non-core revenue, reliance on ramping sales rep headcount for incremental growth, slowed share repurchases due to macro uncertainty, and remaining uncertainty on guideline publication and conversion rates from clinician engagement. Overall, the positives (robust revenue and profit expansion, operational wins, market opportunity) substantially outweigh the negatives.Company Guidance
Consistent Top-Line and Profit Growth
Revenue of $18.6M, up 18.4% year-over-year; 14th consecutive quarter of year-over-year revenue and profit growth. Net income $3.0M, up 58.8%, and diluted EPS $0.35, up 67% versus prior year.
Strong Operating Leverage and Margins
Operating income increased to $3.8M, a 76% increase year-over-year, representing 20.3% of net revenues. Gross profit rose to $14.6M and gross margin expanded to 78.8% from 78.0% (≈ +0.8 percentage points).
Robust Home Care Performance
Direct Home Care revenue of $16.7M (up ~18.6% YoY). Annualized home care revenue per weighted average direct sales representative was $1.168M, exceeding target range of $1.0M–$1.1M.
High Growth in Hospital Channel
Hospital revenue grew 42.5% year-over-year to $1.0M, rebounding after a slower prior quarter and showing diversification across channels.
Solid Balance Sheet and Cash Generation
Cash balance of $17.0M, no debt, working capital of $40M and shareholders' equity of $49.2M. Positive operating cash flow of $6.7M for the nine months ended March 31, 2026; cash increased $1.7M over the prior-year nine-month period.
Commercial and Operational Execution (ePrescribe & Manufacturing)
Smart Order ePrescribe processed over 40% of orders in Q3 and delivered a 5-day reduction in average days-to-ship versus fax orders. Manufacturing optimization plan completed; products assembled in the U.S.; 99% of net revenues generated in the U.S.
Large Addressable Market and Effective Awareness Programs
Company highlighted ~923,000 diagnosed bronchiectasis patients in the U.S. with only 16% receiving HFCWO therapy (large upside). Digital campaign: >2M impressions and >65,000 visits to educational pages. Clinical outreach included 4 regional conferences, 3 national conferences and 4 webinars attended by ~375 clinicians; manuscript showed 58% of qualifying patients not prescribed HFCWO, underscoring market opportunity.
ELMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ELMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $27.20 | $34.03 | +25.11% |
Feb 10, 2026 | $28.06 | $25.26 | -9.98% |
Nov 12, 2025 | $25.38 | $26.35 | +3.82% |
Aug 26, 2025 | $20.66 | $24.77 | +19.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Electromed (ELMD) report earnings?
Electromed (ELMD) is schdueled to report earning on Sep 01, 2026, After Close (Confirmed).
What is Electromed (ELMD) earnings time?
Electromed (ELMD) earnings time is at Sep 01, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ELMD EPS forecast?
ELMD EPS forecast for the fiscal quarter 2026 (Q4) is 0.32.